FHTX (Foghorn Therapeutics) Total Equity: $-81.04 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FHTX Foghorn Therapeutics Inc FHTX
67 GF Score
Price $6.69
GF Value $5.32
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Foghorn Therapeutics Total Equity?

Foghorn Therapeutics FHTX -2.19% 67 Total Equity is $-81.04 Mil as of Jun. 2026. GuruFocus rates FHTX with a GF Score™ of 67/100 and a GF Value™ of $5.32 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Foghorn Therapeutics's total equity for the quarter that ended in Jun. 2026 was $-81.04 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Foghorn Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Foghorn Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Foghorn Therapeutics Total Equity Chart

Foghorn Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 96.87 0.11 -77.19 -45.53 -108.50

Foghorn Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.66 -89.66 -108.50 -76.41 -81.04
FHTX
67GF Score
Foghorn Therapeutics Inc FHTX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Foghorn Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Foghorn Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=198.103-306.603
=-108.50

Foghorn Therapeutics's Total Equity for the quarter that ended in Jun. 2026 is calculated as

Total Equity=Total Assets(Q: Jun. 2026 )-Total Liabilities(Q: Jun. 2026 )
=203.393-284.434
=-81.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-81.04 Mil mean?
Foghorn Therapeutics (FHTX) has a Total Equity of $-81.04 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Foghorn Therapeutics and its competitors.
Is Foghorn Therapeutics' Total Equity too high?
Foghorn Therapeutics' current Total Equity is $-81.04 Mil. Overall, Foghorn Therapeutics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' Total Equity compare to NWBO and FATE?
Foghorn Therapeutics' Total Equity of $-81.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Foghorn Therapeutics and its competitors. Foghorn Therapeutics's current Total Equity is $-81.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.69 — trading 25.8% above its estimated fair value. The current Total Equity is $-81.04 Mil. Foghorn Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current Total Equity is $-81.04 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Foghorn Therapeutics (FHTX) Overvalued in 2026?

Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be overvalued. The current stock price of $6.69 is trading 25.8% above its estimated GF Value™ of $5.32. GuruFocus considers Foghorn Therapeutics to be Modestly Overvalued.

Key valuation signals for FHTX:

  • Total Equity: $-81.04 Mil
  • GF Value™: $5.32 vs. price of $6.69 (25.8% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Foghorn Therapeutics Business Description

Address 99 Coolidge Avenue, Suite 500, Watertown, MA, USA, 02472
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
67GF Score

Get the complete analysis for FHTX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.69
Price
$5.32
GF Value